Prof Old Landgren speaks to ecancer at the 2019 ASH meeting in Orlando about some of the myeloma highlights from this year's conference.
In the newly-diagnosed setting, he mentions that the many new drugs are available provide an opportunity to cut down on treatments that can cause long-term toxicity. He adds that MRD testing can also help deliver deep and sustainable responses, ideally into MRD-negativity.
Prof Landgren goes on to discuss the potential impact of new insights into the biology of the disease that could even lead to curative outcomes.
Finally, he highlights one of the new bi-specific antibodies presented at the meeting that is achieving impressive outcomes.